Diligence memo · auto-generated · as of July 2, 2026
TrialSpark, Inc.
TrialSpark, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
TrialSpark, Inc. operates in Pharmaceuticals, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
TrialSpark, Inc. has raised $372M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $372M on 2024-05-21.
Most recent recorded round closed around 2024-05-21.
Valuation (modeled)modeled
Provath models TrialSpark, Inc. at approximately $4.1B (range $1.8B–$5.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.17× the median modeled value of Series D+ Pharmaceuticals companies in 2022–2024 (18 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Paragon Biosciences Emalex Capital, Inc., Fog Pharmaceuticals, Inc., MAPS Public Benefit Corp, Karyopharm Therapeutics Inc., ADARx Pharmaceuticals, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.